Navigation Links
Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
Date:4/20/2009

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response -

- Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall -

TUSTIN, Calif., April 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that updated preliminary data from the initial cohort of 21 patients in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel showed that 11 of 17 evaluable patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) achieved an objective tumor response according to RECIST criteria, after completing the maximum six treatment cycles. The company also reported that patient dosing is underway in the expansion stage of the trial, which will enroll an additional 28 patients for a total of 49 patients overall.

"We are very pleased to see these additional objective tumor responses in this difficult-to-treat cancer following the full regimen of six treatment cycles of bavituximab and chemotherapy," said Steven W. King, president and CEO of Peregrine. "These updated results build on the impressive data we reported after only four treatment cycles, which had already exceeded the pre-defined number of objective tumor responses needed to expand the trial to the larger cohort."

Mr. King added, "The tumor response data to date from this trial compares favorably to published studies with current standard-of-care lung cancer treatments, and we are looking forward to seeing results from the entire study. With dosing now underway in the expanded patient cohort, we expect to resume the brisk pace of enrollment achieved in the first cohort, with the goal of completing patient
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 2015 A power morcellator lawsuit ( http://www.morcellatorlawsuit2015.com ... for an undisclosed amount, Bernstein Liebhard LLP reports. According ... 2014 in the U.S. District Court, Eastern District of ... widower whose wife had died in February 2013, just ... involved the use of a power morcellator. Following the ...
(Date:7/7/2015)... Juli 2015 Sequent Medical, ein ... Entwicklung innovativer Geräte für die Behandlung neurovaskulärer ... von R. Michael Kleine in den ... verfügt über eine mehr als 25-jährige Erfahrung ... hat verschiedene globale biomedizinische Unternehmen erfolgreich geleitet ...
(Date:7/7/2015)... -- According to a new market research report ... Instrument), Application (Aerobic, Anaerobic, Yeast/ Fungi) & End User (Hospital, ... 2019", published by MarketsandMarkets, The global Blood Culture Tests Market ... Million in 2014 at a CAGR of 7.2% from 2014-2019. ... ma rket data T ables and ...
Breaking Medicine Technology:Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4
... Boston Scientific Corporation (NYSE: BSX ) ... MADIT-CRT trial data in the current issue of the ... showed women received a greater clinical benefit from cardiac ... sub-analysis demonstrated that both men and women experienced significant ...
... CUPERTINO, Calif., Feb. 8, 2011 DURECT Corporation (Nasdaq: ... CreoSalus, Inc., has launched commercial sales of its Food ... Equine, an injectable animal health drug utilizing DURECT,s SABER™ ... a royalty on net sales of SucroMate and will ...
Cached Medicine Technology:Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 2Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 3Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 4DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3
(Date:7/7/2015)... ... July 08, 2015 , ... The National Association of Professional Women (NAPW) ... of the Year Circle. She is recognized with this prestigious distinction for leadership in ... than 700,000 members and over 200 operating Local Chapters. , “I’m pleased to recognize ...
(Date:7/7/2015)... CA (PRWEB) , ... July 07, 2015 , ... ... of patented products, announces the IV Tube Holder, a medical invention that prevents ... medical device market in the world which will be worth $133 billion by ...
(Date:7/7/2015)... ... 2015 , ... Researchers at UC Davis have reviewed a ... and how similar programs can be improved. , Interviewing staff, clinicians and parents ... Practice (HEALTH COP) program, the team identified four factors that helped clinicians successfully ...
(Date:7/7/2015)... ... July 07, 2015 , ... Silverado today issues its first update on construction ... 2015 on a four-acre site in Bellingham, Washington. Cordata Design Review Board approved design ... and other members of the local community. , The new complex – located at ...
(Date:7/7/2015)... ... 07, 2015 , ... Owners of Green Ladies Cleaning are very pleased to ... category. This honor can only be gained by votes from Madison Magazine readership. , ... products and methods they use daily. Having a home cleaned with all-natural products means ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Dr. Alyssa Greedy, Pharm. D., Pharmacy Manager at Walgreens, Into its VIP Woman of the Year Circle 2Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 2Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 3Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 4Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 5Health News:UC Davis Study Identifies Tools, Strategies for Enhancing Obesity Prevention in Rural Communities 2Health News:UC Davis Study Identifies Tools, Strategies for Enhancing Obesity Prevention in Rural Communities 3Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Environmentally-Friendly House Cleaning Company Wins Best of Madison Magazine Award 2
... mantra of Pfizer. The pharmaceutical giant has announced that ... hit by the AIDS virus. The decision by the Pfizer ... winning a landmark case against pharmaceutical companies. In an ... will be given free of cost to battle HIV through ...
... products market in India is expected to grow into a ... India finance report. The big leap is expected to ... billion dollars. Biogenerics, biopharmaceuticals, agriculture, food and nutrition sectors ... internationally. ,The report said the global industry was expected ...
... The world health organisation has come out with a damning ... a message on "No Tobacco Day 2001," World Health Organization ... to the health hazard because most governments still allowed smoking ... agreed that there were no safe permissible levels of second ...
... HIV infected patients on highly active antiretroviral therapy (HAART ... the toxic side effects of the treatment, which causes ... Dr. Raymond T. Chung, who presented the findings at ... toxicity forced almost one in every four patients to ...
... the primary disabling ailments in the world has found a ... 'A double-blind randomised controlled trial of Maharishi Vedic Vibration Technology ... 100 per cent relief from painful arthritis in 36 per ... cent relief from pain in 70 per cent cases. ...
... is a fad these days to sport tattoos. Kids often ... further. Permanent tattoos, which are permanent reminders throughout life, in ... a darker side to the whole affair. The study in ... risk of hepatitis C infection. ,Hepatitis C is a viral ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: